Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Tumor microvascular invasion (MVI) predicts early posthepatectomy HCC recurrence, but usually cannot be determined until the tumor is surgically removed and analyzed histologically. The capability preoperatively to predict MVI and early postsurgical recurrence would represent an advance by informing optimal selection of surgical candidates. Here we show that in combination with a AFP (a tumor biomarker), two Liver Imaging Reporting and Data System (LI-RADS) imaging features (mosaic architecture, corona enhancement) can predict MVI and three features (tumor number, mosaic architecture, absence of intralesional fat) can predict early recurrence.
This abstract and the presentation materials are available to members only; a login is required.